{"id":"https://openalex.org/W6921179982","doi":"https://doi.org/10.6084/m9.figshare.50199","title":") Trypan Blue Exclusion assay for cell survival after 30 min of treatment with inhibitors LY294002, U0126, Bis I, or G\u00f66983 followed by treatment with FGF2 and/or gp120","display_name":") Trypan Blue Exclusion assay for cell survival after 30 min of treatment with inhibitors LY294002, U0126, Bis I, or G\u00f66983 followed by treatment with FGF2 and/or gp120","publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W6921179982","doi":"https://doi.org/10.6084/m9.figshare.50199","mag":"2422679537"},"language":"en","primary_location":{"id":"doi:10.6084/m9.figshare.50199","doi":"https://doi.org/10.6084/m9.figshare.50199","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.50199","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Image"},"volume":null,"type":"other","indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.6084/m9.figshare.50199","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Langford, Dianne","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Langford, Dianne","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006900974","display_name":"Hurford Rosemary","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hurford, Rosemary","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Hashimoto, Makoto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hashimoto, Makoto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081279614","display_name":"Murat H. Digicaylioglu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Digicaylioglu, Murat","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Masliah, Eliezer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Masliah, Eliezer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.8978999853134155,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.8978999853134155,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.009800000116229057,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11872","display_name":"Barrier Structure and Function Studies","score":0.009700000286102295,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fgf2","display_name":"FGF2","score":0.7860000133514404},{"id":"https://openalex.org/keywords/gp120","display_name":"gp120","score":0.9490000009536743},{"id":"https://openalex.org/keywords/hiv","display_name":"HIV","score":0.6110000014305115},{"id":"https://openalex.org/keywords/endothelial-cells","display_name":"endothelial cells","score":0.9430000185966492},{"id":"https://openalex.org/keywords/human-umbilical-vein-endothelial-cells","display_name":"human umbilical vein endothelial cells","score":0.8009999990463257},{"id":"https://openalex.org/keywords/cell-survival","display_name":"cell survival","score":0.6399999856948853},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.6899999976158142},{"id":"https://openalex.org/keywords/u0126","display_name":"U0126","score":0.9459999799728394},{"id":"https://openalex.org/keywords/ly294002","display_name":"LY294002","score":0.9340000152587891},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.6740000247955322},{"id":"https://openalex.org/keywords/signaling-crosstalk","display_name":"signaling crosstalk","score":0.656000018119812}],"concepts":[{"id":"https://openalex.org/C2780070996","wikidata":"https://www.wikidata.org/wiki/Q61482373","display_name":"Trypan blue","level":3,"score":0.8073999881744385},{"id":"https://openalex.org/C3019137385","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell survival","level":3,"score":0.5705999732017517},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.49070000648498535},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.47450000047683716},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.46560001373291016},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4625999927520752},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4058000147342682},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3944000005722046},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3880000114440918},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3675999939441681},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.34929999709129333},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3476000130176544},{"id":"https://openalex.org/C3018023364","wikidata":"https://www.wikidata.org/wiki/Q425265","display_name":"Significant difference","level":2,"score":0.3368000090122223},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.32989999651908875},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.32190001010894775},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.31439998745918274},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.3084999918937683},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.30559998750686646},{"id":"https://openalex.org/C123012128","wikidata":"https://www.wikidata.org/wiki/Q5376430","display_name":"Endothelial stem cell","level":3,"score":0.30480000376701355},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.3021000027656555},{"id":"https://openalex.org/C2780783641","wikidata":"https://www.wikidata.org/wiki/Q738686","display_name":"MTT assay","level":3,"score":0.26820001006126404},{"id":"https://openalex.org/C195687474","wikidata":"https://www.wikidata.org/wiki/Q409715","display_name":"Integrin","level":3,"score":0.2678999900817871},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.262800008058548},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.2590000033378601},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.25769999623298645},{"id":"https://openalex.org/C2779997099","wikidata":"https://www.wikidata.org/wiki/Q7547253","display_name":"Snap","level":2,"score":0.2500999867916107}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.6084/m9.figshare.50199","doi":"https://doi.org/10.6084/m9.figshare.50199","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.50199","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Image"},{"id":"doi:10.6084/m9.figshare.50199.v1","doi":"https://doi.org/10.6084/m9.figshare.50199.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.50199.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Image"},{"id":"mag:2422679537","doi":null,"is_oa":false,"landing_page_url":"https://figshare.com/articles/_Trypan_Blue_Exclusion_assay_for_cell_survival_after_30_min_of_treatment_with_inhibitors_LY294002_U0126_Bis_I_or_G_6983_followed_by_treatment_with_FGF2_and_or_gp120/50199","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"doi:10.6084/m9.figshare.50199","doi":"https://doi.org/10.6084/m9.figshare.50199","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.50199","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Image"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W6977598568","https://openalex.org/W1900874372","https://openalex.org/W113558022","https://openalex.org/W1988232110","https://openalex.org/W2399780225","https://openalex.org/W244014338","https://openalex.org/W2000983328","https://openalex.org/W2099579671","https://openalex.org/W2252862413","https://openalex.org/W2744915457"],"abstract_inverted_index":{"Copyright":[0],"information:Taken":[1],"from":[2,11,89],"\"Signalling":[3],"crosstalk":[4],"in":[5,80],"FGF2-mediated":[6],"protection":[7],"of":[8,38],"endothelial":[9],"cells":[10,58],"HIV-gp120\"BMC":[12],"Neuroscience":[13],"2005;6():8-8.Published":[14],"online":[15],"2":[16],"Feb":[17],"2005PMCID:PMC549045.Copyright":[18],"\u00a9":[19],"2005":[20],"Langford":[21],"et":[22],"al;":[23],"licensee":[24],"BioMed":[25],"Central":[26],"Ltd.":[27],"Trypan":[28],"Blue":[29],"Exclusion":[30],"assay":[31],"for":[32,54,70],"cell":[33],"survival":[34],"after":[35],"30":[36],"min":[37],"treatment":[39,75],"with":[40,60,76,82,99],"the":[41],"MEK":[42],"inhibitor":[43],"U0126":[44],"alone,":[45],"and":[46,62],"followed":[47,73],"by":[48,74,96],"exposure":[49],"to":[50,67,104],"gp120":[51],"and/or":[52],"FGF2":[53,61,77],"24":[55],"h.":[56],"In":[57],"treated":[59],"anti-FGF2,":[63],"HUVEC":[64],"were":[65],"exposed":[66],"anti-FGF2":[68],"antibody":[69],"1":[71],"h":[72],"alone":[78],"or":[79],"combination":[81],"gp120.":[83],"*":[84,91],"Indicates":[85],"a":[86],"significant":[87],"difference":[88],"control.":[90,105],"=":[92],"P":[93],"<":[94],"0.05":[95],"One-Way":[97],"ANOVA":[98],"post-hoc":[100],"Dunnett's":[101],"when":[102],"compared":[103]},"counts_by_year":[],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2025-10-10T00:00:00"}